Manufacturer Supply High Purity API Powder API CAS 1110813-31-4 Dacomitinib

• Powder: Yes
• Customized: Non-Customized
• Certification: GMP, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Solid
• Purity: >99%
• Model NO.: TY-02AL
• CAS: 1110813-31-4
• Appearance: White Powder
• Einecs: 616-396-9
• Assay: 99%
• Shelf: 2 Years
• Transport Package: 25kg/Drum 5g, 100g, 500g, 1kg, 10kg, 100kg, 200kg
• Specification: 25kg/drum
• Trademark: tongyon
• Origin: China
• Production Capacity: 5000kg/Month

Product Description

 

Product name	Dacomitinib
CAS	1110813-31-4
Appearance	white powder
Assay	99%
Storage	Cool and Protect from light

Product Name:Dacomitinib (PF299804)
CAS:1110813-31-4
MF:C24H25ClFN5O2
MW:469.9390032
EINECS:
Mol File:1110813-31-4.mol  
Boiling point:665.7±55.0 °C(Predicted)
Density 1.344
form White solid.
pka12.05±0.43(Predicted)
 


Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib. 
Biological activityDacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2.
Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.
UsesDacomitinib (PF299804), which name is (E)-N-[4-(3-chloro-4-fluoroanilino)-7- methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide, is a potent, orally available, highly selective, irreversible small-molecule tyrosine kinase inhibitor (TKI) of tyrosine kinase human epidermal growth factor receptors (HER) 1 (EGFR), HER2, and HER4. It is most effective against EGFR with IC50 of 6 nM. It is highly effective against NSCLCs carrying EGFR or ERBB2 mutant (anti-Gefitinib) and EGFR T790M mutant.
Clinical StudyDacomitinib has advanced to several Phase III clinical trials. The results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing.



GuangZhou TongYi biochemistry technology Co.,LTD is a company specializing in active pharmaceutical ingredient (API), biology,plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw material. Our company has always adhered to the company philosophy of integrity, professionalism, quality first, and customer service. With the efforts of all the company's employees, it has established long-term and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic and foreign customers. With good comments, our company have made great progress.
Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.

Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.